NCT07082192View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

September 29, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

October 31, 2027

Conditions

ALS (Amyotrophic Lateral Sclerosis)

Interventions

DRUG

Test drug CB03-154 5mg group

One CB03-154 tablet (5mg/tablet) once daily.

DRUG

Test drug CB03-154 10mg group

Two CB03-154 tablets (5mg/tablet) once daily.

DRUG

Test drug CB03-154 15mg group

Three CB03-154 tablets (5mg/tablet) once daily.

DRUG

Placebo Group

Three Placebo tablets once daily.

All Listed Sponsors

lead

Shanghai Zhimeng Biopharma, Inc.

INDUSTRY

NCT07082192 - A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter